Lee Ainslie Rocket Pharmaceuticals, Inc. Transaction History
Maverick Capital LTD
- $5.84 Billion
- Q2 2025
A detailed history of Lee Ainslie (Maverick Capital LTD) transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Maverick Capital LTD holds 8,363,813 shares of RCKT stock, worth $24.3 Million. This represents 0.35% of its overall portfolio holdings.
Number of Shares
8,363,813
Previous 5,199,218
60.87%
Holding current value
$24.3 Million
Previous $34.7 Million
40.91%
% of portfolio
0.35%
Previous 0.68%
Shares
16 transactions
Others Institutions Holding RCKT
# of Institutions
220Shares Held
98.3MCall Options Held
611KPut Options Held
487K-
Rtw Investments, LP New York, NY17.7MShares$51.5 Million0.67% of portfolio
-
Black Rock Inc. New York, NY6.19MShares$18 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.12MShares$17.8 Million0.0% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.82MShares$14 Million0.17% of portfolio
-
Suvretta Capital Management, LLC New York, NY4.14MShares$12.1 Million0.35% of portfolio
About ROCKET PHARMACEUTICALS, INC.
- Ticker RCKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 75,683,696
- Market Cap $220M
- Description
- Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...